InnoCare Pharma Subsidiary Licenses Drug to Eli Lilly for $3.25B

InnoCare Pharma’s subsidiary has entered a licensing agreement with Eli Lilly for a drug candidate, potentially worth up to $3.25 billion in milestone payments.